Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02256033 · ClinicalTrials.gov registry record · Phase 1
Effect of Mild Hepatic Impairment on the Pharmacokinetics of Istradefylline
A Phase 1 study, sponsored by Kyowa Kirin Co..
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT02256033 is a Phase 1 study that has completed, run by Kyowa Kirin Co.. The registered enrollment target is 20 participants.
The verdict
NCT02256033, a Phase 1 study, has completed, sponsored by Kyowa Kirin Co..
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
The purpose of this study is to test whether mild liver impairment affects blood levels of istradefylline in humans. Decreased liver function could possibly increase istradefylline levels.
Interventions
- DRUG Istradefylline
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2014-08 |
| Est. Completion | 2014-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02256033
The ClinicalTrials.gov registry entry for NCT02256033 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kyowa Kirin Co., which has 25 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Istradefylline is the first listed.
NCT02256033 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02256033 about?
NCT02256033 is a clinical study titled "Effect of Mild Hepatic Impairment on the Pharmacokinetics of Istradefylline". The purpose of this study is to test whether mild liver impairment affects blood levels of istradefylline in humans. Decreased liver function could possibly increase istradefylline levels.
What is the current status of trial NCT02256033?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2014-08. Estimated completion is 2014-12.
What interventions are being tested in trial NCT02256033?
The interventions under investigation include: Istradefylline (DRUG).
Who is sponsoring clinical trial NCT02256033?
This trial is sponsored by Kyowa Kirin Co., which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.